logo
CRC signs carbon agreement for National Cement plant near Gorman

CRC signs carbon agreement for National Cement plant near Gorman

Yahoo03-03-2025

A cement plan on Kern's southern border is expected to become California's first to achieve carbon neutrality under an agreement announced Monday between local oil producer California Resources Corp. and its new customer National Cement Co. of California.
Plans call for the 60-year-old facility east of Gorman to transition to produce a less carbon-intensive type of cement while increasing the amount of fuel it sources from local ag waste. Byproduct carbon dioxide will then be transported for permanent burial in Kern County.
Funded in part by a half billion-dollar federal matching subsidy, the project known as Lebec Net Zero is partly a response to a 2021 state law, Senate Bill 596, requiring all cement used in California be net zero by 2045.
The project is expected to create 20 to 25 new jobs when it begins operation as soon as 2031, assuming it wins required approvals.
The memo of understanding the companies signed is another achievement for CRC's subsidiary Carbon TerraVault, which continues to lead Kern's and California's push for greater investment in carbon capture and sequestration. The deal announced Monday brings CTV's carbon management total from pending projects to 9 million metric tons per year of CO2.
CRC President and CEO Francisco Leon said in a news release the agreement underscores increasing demand for innovative decarbonization solutions in California industry.
"Achieving carbon neutrality in the cement industry requires bold action, and this partnership is a critical step in developing the state's first carbon capture, transport, and storage project for this essential sector," he stated.
In the same release, National Cement's CEO, Eric Holard, called the project exciting and transformative.
"We are making a significant investment because we believe in creating a cleaner future and bringing innovation to domestic manufacturing," he stated. "CTV's leadership in safe and responsible carbon management, combined with our strategic and operational alignment, provides a clear pathway for this project being successful.'
CRC confirmed Monday the project must receive a conditional use permit from the county of Kern and undergo an environmental review.
One improvement over National Cement's existing configuration is that the new version will create what's called limestone calcined clay cement, which uses less of the carbon-intensive industrial material called clinker. The U.S. Department of Energy says L3C, as the more climate friendly form is called, will also increase the final product's performance and durability.
Additionally, the project is seen as being more environmentally sustainable because it will reduce the plant's intake of non-biomass fuels such as tires, carpets and petroleum. It will do that because of the biomass-burning capabilities of new kiln technology planned to be installed at the site.
The federal government selected the project for financial support last year along with 32 others in hard-to-decarbonize industries like cement, steel and aluminum production. The Department of Energy called the National Cement project the first carbon capture and sequestration system of its kind in the country.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Yahoo

timea day ago

  • Yahoo

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif., June 10, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company's 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world's most urgent challenges. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. The second leading cause of cancer-related deaths in the U.S., CRC has a 91 percent five-year survival rate if caught in early stages. Yet one out of three eligible adults in the U.S. (over 50 million people) do not complete the recommended screening in part because they find the available options—colonoscopy and stool tests—unpleasant or inconvenient. With Shield, individuals can be screened with a simple blood draw during a routine office visit, helping to detect more cancers early, when they are more treatable. "With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of people who delay their recommended screening for colorectal cancer," said AmirAli Talasaz, Guardant Health co-founder and co-CEO. "This latest honor for Shield recognizes the groundbreaking innovation created by our team at Guardant Health and the world-changing potential of the Shield blood test. By overcoming barriers with current screening methods, we can help increase the overall screening rate, find more cancers at an early stage, and give people more time free from cancer." A panel of Fast Company editors and reporters selected the winners from a pool of more than 1,500 entries and judged applications based on their impact, sustainability, design, creativity, scalability, and ability to improve society. This year's awards are featured on "The World Changing Ideas Awards have always been about showcasing the art of the possible," says Fast Company editor-in-chief Brendan Vaughan. "We're proud to recognize the organizations and leaders that are making meaningful progress on the biggest issues of our time." The Shield blood test was also named to TIME's list of the best inventions of 2024 and selected as a Grand Award Winner in Popular Science's Best of What's New 2024 (Health category). Shield is also the first blood test that is FDA approved for primary screening to be included in The National Comprehensive Cancer Network (NCCN) colorectal cancer (CRC) screening guidelines. Shield is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit About Shield Shield is a non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Michael Weistpress@ +1 317-371-0035

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Business Wire

timea day ago

  • Business Wire

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company's 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world's most urgent challenges. This latest honor for Shield recognizes the groundbreaking innovation created by our team at Guardant Health and the world-changing potential of the Shield blood test. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. The second leading cause of cancer-related deaths in the U.S., CRC has a 91 percent five-year survival rate if caught in early stages. Yet one out of three eligible adults in the U.S. (over 50 million people) do not complete the recommended screening in part because they find the available options—colonoscopy and stool tests—unpleasant or inconvenient. With Shield, individuals can be screened with a simple blood draw during a routine office visit, helping to detect more cancers early, when they are more treatable. 'With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of people who delay their recommended screening for colorectal cancer,' said AmirAli Talasaz, Guardant Health co-founder and co-CEO. 'This latest honor for Shield recognizes the groundbreaking innovation created by our team at Guardant Health and the world-changing potential of the Shield blood test. By overcoming barriers with current screening methods, we can help increase the overall screening rate, find more cancers at an early stage, and give people more time free from cancer.' A panel of Fast Company editors and reporters selected the winners from a pool of more than 1,500 entries and judged applications based on their impact, sustainability, design, creativity, scalability, and ability to improve society. This year's awards are featured on 'The World Changing Ideas Awards have always been about showcasing the art of the possible,' says Fast Company editor-in-chief Brendan Vaughan. 'We're proud to recognize the organizations and leaders that are making meaningful progress on the biggest issues of our time.' The Shield blood test was also named to TIME's list of the best inventions of 2024 and selected as a Grand Award Winner in Popular Science's Best of What's New 2024 (Health category). Shield is also the first blood test that is FDA approved for primary screening to be included in The National Comprehensive Cancer Network (NCCN) colorectal cancer (CRC) screening guidelines. Shield is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit About Shield Shield is a non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.

Shoppable TV: The Next Frontier in Interactive Advertising
Shoppable TV: The Next Frontier in Interactive Advertising

Yahoo

time2 days ago

  • Yahoo

Shoppable TV: The Next Frontier in Interactive Advertising

Film and TV companies are enhancing revenue and data collection through IoT investments, focusing on smart TVs and RFID technologies. IoT aids in asset management and operational efficiency. Key trends include connected TVs and shoppable content, revolutionizing content monetization and advertising. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: The Internet of Things in Film and TV (2025)" report has been added to and TV companies are investing in IoT technologies to enhance revenue, data collection, cost efficiency, and content monetization. Film and TV companies are increasing investment into IoT initiaves and will continue to do use in film and TV will increase in the coming yearsThe Internet of Things, or IoT, could benefit film and TV companies significantly. Some of the use cases of IoT in the industry include connected devices like smart TVs and radio-frequency identity (RFID) tags, which can help production companies manage and track their physical and digital assets, improving operational efficiency. Companies must invest time and money to understand relevant IoT technologies, build the necessary skill sets, and establish strategic partnerships to take full TVs are a key IoT technology for film and TVThe widespread adoption of smart TVs, or connected TVs (CTVs), by consumers has significant implications for content creation, distribution, and viewer engagement. In the UK, 86% of primary TV sets were connected to the internet in 2024, according to Ofcom. CTVs enable companies to gather user data and create personalized viewing experiences that can set their products apart in a competitive market. Content providers should partner with CTV manufacturers and platform operators to secure bespoke deals. Such collaborations may include agreements on data sharing, preferential content placement in search algorithms, and content bundling packages. Additionally, by integrating technologies such as voice control, CTVs can enhance the offerings of film and TV TV is the future of TV advertisingFacilitated by the widespread adoption of CTVs, shoppable television is rapidly transforming the landscape of advertising and content consumption within the industry. Shoppable content integrates e-commerce directly into the viewing experience, allowing audiences to purchase products featured in shows and advertisements. It capitalizes on the growing trend of second-screen shopping, especially among younger demographics, while providing a new level of interactivity that traditional advertising cannot. Shoppable TV allows vertically integrated companies like Amazon to merge their entertainment and retail business interests and share data Internet of Things, or IoT, could benefit film and TV companies significantly. Some of the use cases of IoT in the industry include connected devices like smart TVs and radio-frequency identity (RFID) tags, which can help production companies manage and track their physical and digitalassets, improving operational efficiency. Companies must invest time and money to understand relevant IoT technologies, build the necessary skill sets, and establish strategic partnerships to take full Scope This report provides an overview of the internet of things theme and how it will impact the film and TV industry. The report predicts how the internet of things in film and TV will evolve, including the key challenges it will solve. It includes selected case studies highlighting who is innovating in film and TV using internet of things technologies The report also includes a comprehensive data analysis, including market size and growth forecasts for the future of work. Reasons to Buy The thematic research ecosystem is a single, integrated global research platform that provides an easy-to-use framework for tracking all themes across all companies in all sectors. This report is essential for senior executives at film and TV companies to understand the critical benefits from integrating internet of things technology into their operations. Film and TV companies who fail to implement internet of things solutions will fall behind. In addition, the report identifies the leading internet of things adopters in film and TV, as well as specialist tech vendors in this space. Key Topics Covered: Executive Summary Players Value Chain The Impact of IoT on Film and TV Case Studies The IoT Timeline Companies Sector Scorecard Company Coverage Includes: Accenture Acer Alteryx Alibaba Alibaba Pictures Alphabet (Google) Amazon AMC Entertainment AMC Networks AMD Apple Arista Networks Arup Atos Atresmedia Baidu Bain & Company Bentley Systems Bilibili Bosch Broadcom ByteDance Capgemini Cisco Cloudera Cognex Cognizant Curry's Dataiku DataStax Dell Technologies Deloitte Deutsche Telekom DiO DXC Technology Ericsson EY Fortinet Fujitsu GAO RFID Google Grupo Televisa Haier HCLTech Hitachi Vantara Hikvision Honeywell Humax Huawei IBM Infineon Informatica Intel ITV JVC Juniper Networks KPMG Konka Kyndryl LG Electronics Lenovo Lionsgate Live Nation M6-Metropole TV MediaForEurope MediaTek Meta Microsoft MongoDB Naspers Netflix Network 18 Media Nexstar Nokia Nvidia Oracle Panasonic Paramount Paramount Global Philips PwC ProSiebenSat.1 Rakuten RCA Roku Rockwell Automation Samsung Electronics Samsung SDS SAS Schneider Electric Seiki Sierra Wireless Siemens Snap Snowflake Software AG Sony Spotify Splunk Talend Tata Consultancy Services Tech Mahindra Tegna Teradata Texas Instruments Tietoevry Toshiba Universal Music Uscreen Vantiva Veritas Viaplay Vivendi Walt Disney Warner Bros. Discovery Warner Music Wipro X (formerly Twitter) Xiaomi Zee Entertainment ZTE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store